

1 **Distinct secretomes in p16- and p21- positive senescent cells across tissues**

2
3 Dominik Saul, M.D.^{1,2,3}, Diana Jurk, Ph.D.^{2,4}, Madison L. Doolittle, Ph.D.^{1,2}, Robyn Laura Kosinsky,
4 Ph.D.⁵, David G Monroe, Ph.D.^{1,2}, Nathan K. LeBrasseur, Ph.D.^{2,4}, Paul D. Robbins, Ph.D.⁶, Laura
5 J. Niedernhofer, M.D., Ph.D.⁶, Sundeep Khosla, M.D.^{1,2}, and João F. Passos, Ph.D.^{2,4}

6
7 **Affiliations:**

8 ¹Division of Endocrinology, Mayo Clinic, Rochester, MN 55905, USA

9 ²Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, USA

10 ³Department of Trauma and Reconstructive Surgery, BG Clinic, University of Tübingen, Tübingen,
11 Germany

12 ⁴Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA

13 ⁵Robert Bosch Center for Tumor Diseases, Stuttgart, Germany.

14 ⁶Institute on the Biology of Aging and Metabolism, Department of Biochemistry, Molecular Biology
15 and Biophysics, University of Minnesota, Minneapolis, MN, USA.

16
17
18
19
20 ***Correspondence:**

21 Dr. Sundeep Khosla Division of Endocrinology, Mayo Clinic, Mayo Clinic, 200 First Street SW,
22 Rochester, MN 55905, USA, Khosla.Sundeep@mayo.edu

23 Dr. João F. Passos Department of Physiology and Biomedical Engineering, Mayo Clinic, 200 First
24 Street SW, Rochester, MN 55905, USA passos.joao@mayo.edu

25

26

27 **Emails:**

28 • Dominik Saul: saul.dominik@mayo.edu; ORCID: 0000-0002-0673-3710
29 • Diana Jurk: jurk.diana@mayo.edu ORCID: 0000-0003-4486-0857
30 • Madison L. Doolittle: doolittle.madison@mayo.edu; ORCID: 0000-0003-0912-0095
31 • Robyn Laura Kosinsky: robyn-laura.kosinsky@bosch-health-campus.com; ORCID: 0000-
32 0003-2869-7762
33 • David G. Monroe: monroe.david@mayo.edu, ORCID: 0000-0002-4818-0114
34 • Nathan LeBrasseur: lebrasseur.nathan@mayo.edu, ORCID: 0000-0002-2002-0418
35 • Paul Robbins: probbins@umn.edu, ORCID: 0000-0003-1068-7099
36 • Laura Niedernhofer, Iniedern@umn.edu, ORCID: 0000-0002-1074-1385
37 • Sundeep Khosla: khosla.sundeep@mayo.edu; ORCID: 0000-0002-2936-4372
38 • Joao Passos: passos.joao@mayo.edu; ORCID: 0000-0001-8765-1890

39 **SUMMARY (148 words)**

40 Senescent cells drive age-related tissue dysfunction via the induction of a chronic senescence-
41 associated secretory phenotype (SASP). The cyclin-dependent kinase inhibitors p21^{Cip1} and
42 p16^{Ink4a} have long served as markers of cellular senescence. However, their individual roles
43 remain incompletely elucidated. Thus, we conducted a comprehensive examination of multiple
44 single-cell RNA sequencing (scRNA-seq) datasets spanning both murine and human tissues
45 during aging. Our analysis revealed that p21^{Cip1} and p16^{Ink4a} transcripts demonstrate significant
46 heterogeneity across distinct cell types and tissues, frequently exhibiting a lack of co-expression.
47 Moreover, we identified tissue-specific variations in SASP profiles linked to p21^{Cip1} or p16^{Ink4a}
48 expression. Our study underscores the extraordinary diversity of cellular senescence and the
49 SASP, emphasizing that these phenomena are inherently cell- and tissue-dependent. However,
50 a few SASP factors consistently contribute to a shared "core" SASP. These findings highlight the
51 need for a more nuanced investigation of senescence across a wide array of biological contexts.

52 **INTRODUCTION**

53 Cellular senescence is characterized by not just an irreversible cell-cycle arrest but also
54 the development of various functional and morphological alterations in distinct cell compartments,
55 such as the nucleus, lysosomes, mitochondria, and others^{1,2}. The senescent cell-cycle arrest is
56 largely mediated by cyclin-dependent kinase inhibitors such as p21^{CIP1} (p21 encoded by
57 *CDKN1A*) and p16^{INK4A} (p16 encoded by *CDKN2A*)². Cellular senescence also exhibits a
58 senescence-associated secretory phenotype (SASP), which comprises a diverse array of
59 secreted factors including immune-modulatory cytokines and chemokines, matrix remodeling
60 enzymes, and growth factors³. Senescent cells play crucial roles in development, tumor
61 suppression, and tissue repair⁴⁻⁶. However, as individuals age, the accumulation of these cells
62 has been linked to the onset of various age-related conditions. Additionally, the removal of
63 senescent cells either genetically or pharmacologically enhances functional outcomes in mice
64 within the context of aging and age-related diseases, underscoring the therapeutic potential of
65 targeting these cells⁷.

66 Even though there are numerous molecular changes associated with senescent cells,
67 detecting these cells within tissues remains exceedingly challenging. Central to this difficulty is
68 the absence of a singular specific marker for the unequivocal identification of senescent cells, as
69 none of the markers conventionally employed in senescence detection exhibit individual
70 specificity. Adding to this complexity, senescent cells and their SASP exhibit variability contingent
71 upon the specific physiological context, cell type, and tissue type under investigation⁸.

72 The recent advancements in single-cell omics technologies offer a unique opportunity to
73 comprehensively unravel the heterogeneity of the senescent phenotype across various cell types
74 and tissues⁹. One of the key unresolved questions concerns the relative contributions of p16 and
75 p21, which have been identified as critical drivers of cellular senescence, towards age-related
76 senescence across different tissues *in vivo*. Through the analysis of multiple scRNA-seq datasets
77 across diverse murine tissues (brain, skeletal muscle, bone, and liver) and in human skin and

78 lung during aging, we observed that expression of p16 and p21 occurs in tissue-specific cell types
79 which exhibit unique, often non overlapping SASP profiles, suggesting that these sub-populations
80 have distinct functional roles. Furthermore, our findings indicate that while there are
81 commonalities in SASP profiles in p16 and p21 expressing cells, these vary considerably
82 according to tissue- and cell-type. However, only a small number of SASP markers can be
83 considered as part of a "core" set. Our comprehensive analysis underscores the intricate nature
84 of cellular senescence and the SASP, emphasizing the important role of single-cell studies to fully
85 elucidating and characterizing senescence in aging tissues.

86

87 RESULTS

88 Unraveling p16- vs. p21-associated SASP in the murine brain

89 Previous studies have shown that markers of cellular senescence increase during aging
90 in murine brain and, importantly, that clearance of p16+ cells enhances cognitive function in aged
91 mice¹⁰. To further investigate cellular senescence in the brain, we conducted an in-depth analysis
92 of scRNA-sequencing datasets¹⁰ to profile and compare the cellular composition and
93 transcriptomes of young (4m) and old mouse (24m) hippocampi; a brain region known for its
94 involvement in memory formation. Our analysis initially identified five primary cell populations
95 within the hippocampus (**Fig.1a**). To mitigate potential confounding factors introduced by
96 inflammatory immune cells, we refined our focus by excluding CD45^{high} cells. This criterion still
97 allowed the inclusion of microglia in our analysis which are characterized by CD45^{low/intermediate}
98 expression¹¹. Further filtering steps involved ensuring the absence of the proliferation marker Ki67
99 (*mKi67*) and verifying that the selected cells were not in the S phase since senescent cells are
100 arrested in G1/2 phases of the cell-cycle¹². Subsequently, p16(*Cdkn2a*)-positive cells and
101 p21(*Cdkn1a*)-positive cells were isolated. Among the p16+ cells, microglia and oligodendrocytes
102 appeared as the main subpopulations, whereas in the p21+ cells, microglia predominated
103 (**Fig.1b**).

104 This analysis revealed the presence of 3 subpopulations, 1) cells exclusively expressing
105 p21; 2) cells exclusively expressing p16; and 3) cells expressing both p21 and p16 (**Fig.1c, d**).
106 To gain deeper insights into the composition of the SASP within these identified subpopulations,
107 we leveraged our previously established SenMayo gene set¹³, which has been demonstrated to
108 be commonly regulated across various age-related transcriptome datasets. We observed a
109 distinct SASP profile for p21+ and p16+, characterized by a limited overlap in SASP gene
110 expression. Notably, only two genes, *Cxcl16* and *Plaur*, were found to be expressed in both
111 subpopulations (**Fig.1e**). Likewise, when we analyzed an extensive list of secreted proteins not
112 limited to the known SASP¹⁴ plus SenMayo, we observed a limited overlap in gene expression
113 between p21+ and p16+ cells. Only four genes, *Col8a2*, *Plaur*, *Cxcl16* and *Fbln5* were found to
114 be shared between these two subpopulations (**Extended data Fig. 1**).

115 Overall, these data emphasize the diversity as well as variability in SASP profiles among
116 cells with core features of senescence in the brain.

117 **Comparing p16 and p21-associated SASP across murine tissues**

118 After our initial observations in the brain, we extended our investigation to assess the generality
119 of our findings in diverse murine tissues during aging. We specifically focused on skeletal muscle,
120 bone, and liver, as previous research had indicated age-dependent rises in senescence-
121 associated markers and demonstrated the benefits of eliminating senescent cells for the
122 functional outcomes of these organs¹⁵⁻¹⁷. We used single-cell RNA-seq datasets comparing young
123 and old mice. In total, we successfully identified 9, 14, and 13 distinct cell populations in skeletal
124 muscle (**Fig.2a**), bone (**Fig.2d**), and liver (**Fig.2g**), respectively. We then followed a similar
125 methodology as in our brain analysis, excluding cells that were positive for Ki67 and in the S-
126 phase of the cell cycle, as well as CD45^{high} cells.

127 In our examination of all three tissues (**Fig. 2**), we observed a consistent pattern. We identified
128 distinct cell subsets that exclusively expressed either p21 or p16, and a rare subgroup of cells
129 that co-expressed both markers (**Fig.2b, e & h**). Notably, in all three tissues, the population of

130 cells expressing p21 was considerably more abundant. Our analysis utilizing the SenMayo
131 dataset revealed that the trend found in brain extended across tissues: a limited set of SenMayo
132 factors were uniquely expressed by p16+ cells, while p21+ cells exhibited a broader range of
133 SenMayo factors (**Fig.2c,f & i**). Although a small number of genes were co-expressed by cells
134 positive for both p16 and p21, these were not consistently shared among the three tissues.
135 Indeed, our investigations suggest that there is a distinctiveness in the composition of SASP
136 profiles for each tissue, irrespective of the expression of p21 and p16. If we extend our analysis
137 to a larger set of genes including an extensive list of secreted proteins plus SenMayo, we observe
138 a similar pattern across murine tissues with p21+ cells being associated with a more abundant
139 secretory profile and a limited overlap between the secretory profile of p21+ and p16+ cells
140 (**Extended Data Fig. 2a-c**).

141 This observation aligns with transcriptomics data from a previous study, where the overexpression
142 of p21 and p16 in mouse embryonic fibroblasts (MEFs) resulted in distinct SASP profiles¹⁸. Certain
143 factors were unique to either p21 or p16 overexpressing senescent cells, with some overlap
144 (**Extended Data Fig. 3**).

145 Furthermore, to investigate if our findings extend to the protein level, we conducted an analysis
146 using data derived from mass cytometry by time-of-flight (CYTOF) conducted on the bones of
147 young and aged mice¹⁹. This technique provided a detailed examination of cell-type and
148 senescence-associated protein markers at the single-cell level (**Fig.2 j**). Similar to the scRNASeq
149 analysis, we excluded cells positive for Ki67 and CD45. Our analysis revealed distinct subsets of
150 cells expressing either p21 or p16 exclusively, along with a rare subgroup co-expressing both
151 markers at the protein level (**Fig.2 k**). It is important to note that CYTOF methodology relies on
152 targeted panels of antibodies, which limited our analysis of SASP components. Nevertheless, we
153 identified proteins such as Serpine1 exclusively expressed in p16+ cells and IL6 exclusively
154 expressed in p21-positive cells, reinforcing the existence of distinct SASP profiles (**Fig. 2 j-l**).

155 **Comparing p16- and p21-dependent SASP in human tissues during aging**

156 Subsequently, we aimed to assess the consistency of our findings across species. To achieve
157 this, we analyzed scRNA-seq datasets from human skin and lung tissues during aging^{20,21}. To
158 examine human skin, we utilized a recently published dataset in which scRNA-sequencing was
159 conducted on human eyelid skin samples from individuals spanning an age range of 18 to 76
160 years²⁰. Here, we identified 16 distinct cell populations (**Fig.3a**). We then proceeded to remove
161 Ki67+, CD45^{high} and S-phase cells and observed three subpopulations: p21-exclusive, p16-
162 exclusive, and p21-p16 co-expressing cells, with p21-exclusive being the predominant group
163 (**Fig.3b**). Interestingly, by utilizing the SenMayo dataset, we identified no overlap between p21
164 and p16 expressing cells, underscoring their distinctiveness as separate cell populations (**Fig.3c**).
165 A similar pattern was observed in human lung. Here we utilized a recently published scRNA-seq
166 dataset from healthy human lungs ranging from 21 to 78 years of age²¹. Within our analysis, we
167 identified 18 distinct cell populations (**Fig.3d**). After excluding Ki67+, CD45^{high} and S-phase cells,
168 we observed that a significant majority of cells displayed p21 expression, while only a small
169 number of cells exhibited p16 or the combination of p16 and p21 (**Fig.3e**). Notably, cells that were
170 p16+ demonstrated limited expression of SenMayo components, with *Serpine1* being the
171 exclusive gene expressed by this subgroup. In contrast, p21+ cells exhibited the expression of
172 multiple SenMayo components (**Fig.3f**). When we broaden our examination to include a wider
173 range of genes which involves a comprehensive list of secreted proteins²² alongside SenMayo¹³,
174 we observed that there are relatively few SASP/secreted protein genes that are common between
175 p21 and p16 expressing cells in both human skin and lung (**Extended Data Fig. 4a & b**). This
176 further underscores the functional specificity inherent in these sub-populations.

177 **Common p16 and p21 SASP across murine and human tissues**

178 Following our identification of significant heterogeneity in the SASP genes expressed between
179 p16+ and p21+ senescent cells among tissues in both murine and human subjects, we sought to
180 investigate which elements exhibit commonality across diverse tissues and species (**Fig.4a and**
181 **b**). When investigating the p16+ SenMayo gene set, we noticed that only a portion of SenMayo

182 genes were expressed in two or more of the analyzed tissues. This subset included *Spp1*, *Cd9*,
183 *Mif*, *Ctsb*, *Mmp2*, *Igfbp6*, *Hmgb1* and *Igfbp4* (**Fig.4c**).
184 In the case of p21, we observed that *Icam1* and *Jun* were consistently expressed across all six
185 analyzed tissues, while several other factors, including *Cxcl16*, *Il6*, *Pgf*, *Ets2*, *Igfbp4*, *Igfbp6*,
186 *Igfbp7*, *Bmp2*, *Gem*, *Serpine2*, *Ptges*, and *Edn1*, were expressed in four or more of the six
187 analyzed tissues (**Fig.4d**). Combining p16 (red) and p21 (blue) markers that are expressed in
188 more than two (p16) and four (p21) tissues, a “core” SASP comprised of *Jun*, *Igfbp4*, *Igfbp6* and
189 *Spp1* is established. While *Jun* may exhibit a stronger association with p21, *Igfbp4* and *Igfbp6* are
190 prominently expressed by both cell types, suggesting these as “common” SASP factors (**Fig.4e**).
191 In our search for a common SASP signature, we broadened our analysis to encompass a greater
192 number of secreted factors, in conjunction with SenMayo. This approach enabled us to identify
193 16 genes expressed in p16+ cells that were consistently present in (at least) 3 of the analyzed
194 tissues (**Fig. 4f**). In p21+ cells, we identified 50 distinct genes expressed in a minimum of four
195 tissues, among which 5 genes were expressed in five tissues, and a single gene, *Jun*, was
196 expressed in all analyzed tissues (**Fig. 4g**). Interestingly, this factor, along with *Edn1*, has been
197 previously identified by SenMayo. In contrast, *Col18a1*, *F3*, *Nampt* and *Sdc4* are expressed
198 across five tissues and are not associated with SenMayo. Upon combining all factors to identify
199 a “common” SASP, we observed that *Jun* remains abundant primarily in p21+ cells. Additionally,
200 *Sparc* is expressed in 3 out of 6 tissues by p16+ cells and in 4 out of 6 tissues by p21+ cells,
201 thereby establishing it as another “common” SASP marker. (**Fig. 4h**).
202

203 **Heterogeneous intercellular communication highlights the functional diversity of p21+ and**
204 **p16+ cells**

205 The SASP plays a crucial role in intricate intercellular communication, exerting complex effects
206 on neighboring cells. These effects include the propagation of senescence²³, modulation of tissue
207 repair processes^{6,24,25}, and recruitment of immune cells²⁶. We sought to determine if senescence

208 sub-types (p21+ and p16+ cells) not only differed in their transcriptomes, but also in how they
209 communicate with other cells. Thus, we utilized CellChat, a commonly used tool for inference of
210 cell-cell communication²⁷. Our analysis focused on both p21+ and p16+ cells and their interactions
211 with neighboring cell types across the mentioned tissues. An initial pairwise examination of the
212 communication patterns of these specific p21+ or p16+ cells within each tissue shows a
213 heterogeneity for the most important 17 signaling pathways (**Fig. 5a**). A more detailed examination
214 in each tissue shows that in brain (**Fig. 5b**), p21+ cells mostly used the CCL and JAM-pathway
215 for communication with microglia, while p16+ cells favored the MAG-pathway to communicate
216 with oligodendrocytes. In bone (**Fig. 5c**), p21+ cells used the THBS- and FN1-pathway exclusively
217 to communicate with hypertrophic chondrocytes and osteolineage cells, while p16-positive cells
218 utilized other mechanisms. In skin (**Fig. 5d**), the CD99-pathway was favored by p16+ cells and
219 the DESMOSOME-pathway by p21+ cells to communicate to granular and spinous cells as
220 sebocytes. Muscle (**Fig. 5e**) was characterized by a low number of p16+ cells and a high secretory
221 pattern of the p21+ cells, which mostly used the LAMININ pathway to communicate with Fibro-
222 Adipogenic Progenitors (FAPs) and tendon cells. In liver (**Fig. 5f**), p21+ cells favored the JAM
223 pathway to communicate with myofibroblasts and hepatic progenitors, while p16+ cells used the
224 CDH5-pathway for communicate with endothelial and Kupffer cells. In lung (**Fig. 5g**), the FN1-
225 pathway was more used by the p16+ cells, while p21+ cells favored the MIF-pathway. These
226 findings emphasize that the diversity of the p21 and p16-dependent SASP across different tissues
227 reflects the intricate nature of intercellular communication.

228 This heterogeneity becomes apparent when exploring the transcription factors that control gene
229 expression in p16+ and p21+ cells. To achieve this, we employed SCENIC, a computational
230 method that allows the prediction of interactions between transcription factors and target genes
231 based on single-cell RNA-seq data²⁸. SCENIC analyses reveal that transcription factors regulating
232 gene expression in p16 (**Extended data Fig. 5a & b**) and p21 (**Extended data Fig. 5c & d**)
233 positive cells are mostly tissue specific, with minimal overlap between tissues. This implies that

234 the SASP is not exclusively specific to p16+ or p21+ cells; rather, these senescent subtypes are
235 further transcriptionally regulated by factors specific to the tissue in which they are situated.
236 In summary, the diversity in cellular communication and transcriptional regulation between p16+
237 and p21+ cells within the unique environments of the six analyzed tissues underscores their
238 heterogeneity and suggests potentially distinct functions.

239 **Discussion**

240 p21 and p16 are both associated with the induction of senescence, but they do not always occur
241 together in senescence. Multiple studies *in vitro* have shown that their presence and expression
242 can vary depending on the senescence-inducing stimuli, the cell type, and the specific context²⁹.
243 p21 is a direct target of the tumor suppressor protein p53. When DNA damage or other stressors
244 occur, p53 becomes activated and binds to the p21 promoter, leading to increased p21
245 expression. p21, in turn, inhibits the activity of cyclin-dependent kinases (CDKs), halting the cell
246 cycle and promoting senescence. p16, on the other hand, acts through the Retinoblastoma (Rb)
247 pathway³⁰. p16 inhibits CDK4 and CDK6, which are responsible for phosphorylating Rb. When
248 Rb is not phosphorylated, it remains active and prevents the cell from progressing through the
249 cell cycle. Both pathways are intricate as they involve numerous upstream regulators and
250 downstream effectors, as well as the presence of diverse side branches. Furthermore, these
251 pathways exhibit substantial interconnections and crosstalk³¹.

252 p16 and p21 are widely employed as the two most common markers for identifying senescent
253 cells. Their bulk expression has been extensively utilized to identify senescent cells in different
254 tissues affected by aging or other pathological conditions². However, only recently, with the
255 advancement of single-cell omics technologies, can we truly examine the full extent of their
256 heterogeneity *in vivo*³².

257 Our study clearly demonstrates that, in various aging tissues, cells expressing p21 and p16 at
258 both the transcript and protein levels frequently constitute separate subpopulations characterized
259 by distinct SASP compositions. This suggests the activation of these two pathways may result in

260 functionally diverse consequences and is reflected in the engagement of different intercellular
261 communication pathways. Nevertheless, it is plausible that some of these cells are at varying
262 stages of senescence induction, with p21 being triggered earlier following exposure to a stressor
263 and p16 being induced in a later stage of senescence as previously shown *in vitro*³³. Consistent
264 with the functional diversity of these sub-populations, a recent study has demonstrated that p21
265 and p16 overexpression elicit distinct SASPs, with p21's SASP promoting immunosurveillance¹⁸.
266 p21 upregulation has also been suggested as a mechanism that enables senescent cells to resist
267 apoptosis thereby facilitating their retention in tissues³⁴. Moreover, recently developed transgenic
268 models where either p21+ or p16+ cells can be cleared have been shown to have different
269 functional outcomes. For example, selective elimination of p21+ senescent cells, as opposed to
270 p16+ ones, effectively prevents radiation-induced osteoporosis³⁵.
271 Interestingly, the composition of SASP in cells expressing p21 and p16 exhibited significant
272 variation across different tissues, with only a limited number of common SASP factors. This
273 observation holds significant conceptual implications. It indicates that the phenotypes resulting
274 from the activation of senescence-associated pathways during aging are strongly influenced by
275 the specific cell type involved. Moreover, it raises the intriguing possibility that distinct intrinsic
276 mechanisms may contribute to senescence in various tissue types during aging. Finally, it
277 suggests that analysis of SASP components in tissues should be comprehensive in nature and
278 conducted at single-cell resolution.
279 Our findings hold significant implications for the implementation of senolytic therapies in clinical
280 contexts. They underscore the importance of adopting a context-specific approach not just taking
281 into consideration the subtype of senescent cells, but also the tissue which is being targeted.
282
283 **Materials and methods**
284
285 *Single-cell analysis.*

286 The scRNA-seq data were aligned and quantified using the 10X Genomics Cell Ranger Software
287 Suite (v6.1.1) against the murine reference genome (mm10) and human reference genome
288 (hg19). The Seurat package (v4.3.0.1 and 5.0.0) (PMID: 29608179, PMID: 31178118) was used
289 to perform integrated analyses of single cells. Genes expressed in <3 cells and cells that
290 expressed <200 genes and >20% mitochondria genes were excluded from downstream analysis
291 in each sample. The datasets were SCTransform-normalized and the top 3000 highly variable
292 genes across cells were selected. The datasets were integrated based on anchors identified
293 between datasets before Principal Component Analysis (PCA) was performed for linear
294 dimensional reduction. After normalization and scaling, a shared nearest neighbor (SNN) Graph
295 was constructed to identify clusters on the low-dimensional space (top 30 statistically significant
296 principal components, PCs). An unbiased clustering according to the recommendations of the
297 Seurat package was used, if not provided by the authors. The cell types were assigned according
298 to the authors' recommendations or provided metadata. The alluvial plots were designed with the
299 ggalluvial package (v0.12.5). For the DimPlots, the RNA-slot was used and every value above 0
300 was counted as "positive". The differentially expressed markers were identified by the
301 FindMarkers function (ident.1 was specified, and differences calculated to all other clusters) and
302 the Wilcoxon signed-rank test. We used the SenMayo gene set (n=125) or secreted proteins,
303 obtained by the human protein atlas, augmented by the SenMayo secreted SASP factors
304 (n=1989²²) to select the SASP factors or secreted proteins. The cytoscape bubble plot were
305 designed with cytoscape (v3.1.0), and the size of each bubble is proportional to the avg_log2FC.
306 The circular plots were designed with ggplot2 (v3.4.4). The spider plots were designed with the
307 package fmsb (v0.7.5). The circle size is proportional to the log2FC compared to all other clusters,
308 while the color codes the respective tissue. The bars show the median of all tissues in which the
309 respective gene is upregulated.
310 For the intercellular communication heatmap, we first calculated the respective intercellular
311 communication via CellChat (v1.6.1). The centrality values were extracted and used for the central

312 heatmap for which we used GraphPad Prism (Version 9.0). The probability of the inferred
313 communication was used for the sankey-network. The depiction of the sankey-network was done
314 via the networkD3 package (v0.4) and exported via jsonlite (v1.8.7). Since muscle had too little
315 p16+ cells for the CellChat analyses, these were excluded.

316 For the SCENIC analyses, we used the standard settings (v.1.3.1). For plotting the most important
317 factors, the relative activity for each transcription factor above 1 was chosen for p21+ and p16+
318 cells, respectively, *per* tissue. Since liver has very few p16+ cells for proper calculation with
319 SCENIC, these were excluded. For the pie charts, the sum of transcription factors sharing a tissue
320 was calculated and the respective percentage is demonstrated within the plot.

321

322 *Cytometry by time of flight (CyTOF) analysis.*

323 The provided fcs-files were read into R by the flowCore package (v2.8.0) and transformed into a
324 Seurat object. All subsequent analyses were following the standard Seurat procedure as
325 described above.

326

327 *RNA-sequencing analysis.*

328 The fastq files were mapped to the murine genome (mm10), and analysis was performed using
329 the DESeq2 package (v1.38.3) as previously described¹³. Significantly differentially regulated
330 genes were selected by a Benjamini–Hochberg adjusted p value <0.05 and log2-fold changes
331 above 0.5 or below –0.5.

332

333 *Statistics.*

334 Statistical analyses were performed using either GraphPad Prism (Version 9.0) or R version 4.2.0.
335 A p-value <0.05 (two-tailed) was considered statistically significant.

336

337 *Code availability.*

338 The code for each figure will be provided by the first author upon reasonable request.

339

340 **Acknowledgements**

341 This research was supported by the NIH through grants P01 AG062413 (to S.K., N.K.L., D.M.,

342 D.J., L.J.N., P.D.R. and J.F.P.), R01AG068048 (to J.F.P.), R01AG82708 (to J.F.P.),

343 UG3CA268103 (to J.F.P.), R01 AG068182 (to D.J.), R01 AG063543 (L.J.N), Hevolution/AFAR

344 (to D.J.), R01 AG076515 (to S.K, D.M., P.D.R., L.J.N.), U54 AG079754 (to S.K., N.K.L., P.D.R.,

345 L.J.N.), R01 AG055529 (to N.K.L), U54 AG076041 (to L.J.N., P.D.R.) and U19 AG056278 (to

346 P.D.R., L.J.N.).

347 **Author contributions**

348 All authors contributed to writing the manuscript and reviewed and approved of its submission for

349 publication. D.S., S.K. and J.F.P conceived and directed the project. D.S. analyzed and

350 interpreted the data with input from S.K. and J.F.P. M.L.D, N.K.L., P.D.R., L.J.N., D.J., R.L.K,

351 D.G.M. contributed to the conceptual development of the project.

352

353 **Competing interests**

354 The authors declare no competing interests.

355 **Main Figure Legends**

356 **Figure 1: Distinct p16+ and p21+ cell populations with differential SASPs in the murine**

357 **hippocampus** (a) A tSNE plot depicting the five main populations of young and old murine

358 hippocampus (PMID: 33470505, GSE161340). (b) From the original population, CD45- cells are

359 selected, followed by Ki67-negativity and cells not in the S phase. From these cells, just

360 p16(*Cdkn2a*)+ cells and p21(*Cdkn1a*)+ cells are selected. From the p16+ cells, microglia and

361 oligodendrocytes depict the main populations, while in the p21+ population, microglia is

362 predominant. (c) tSNE visualization of p16 (red) and p21 (blue) cells, along with few double-

363 positive cells (green), shown in the Cd45-Ki67-S- population. (d) The dPo (double positive) cells

364 are high in both *Cdkn2a* and *Cdkn1a* while p16+ cells just express *Cdkn2a*, but no *Cdkn1a* and

365 vice versa. (e) Utilizing the SenMayo gene set, SASP factors exclusively expressed by p16+ cells

366 are fewer than those expressed in p21+ cells, with some (*Cxcl16*, *Plaur*) being expressed by both.

367 Very few SASP genes are expressed by p16-negative and p21-negative cells. The size of the

368 dots represents the fold change compared to all other populations shown in (c).

369 **Figure 2: Comparative analysis of p16+ and p21+ cells and their SASP in different murine**

370 **tissues during aging.** (a) In murine skeletal muscle (PMID: 36147777, GSE172410), nine

371 different cell types can be distinguished. (b) p21+ cells constitute the majority, while double

372 positive (dPo) cells are infrequent. (c) The SASP is heterogeneous, with p21+ cells expressing a

373 vast array of SASP factors, exhibiting minimal overlap with p16-associated SASP factors. (d) In

374 murine bone (PMID: 31130381, GSE128423), 17 cell types can be distinguished. (e) p21+ cells

375 once again dominate the senescent cell population, and the (f) SASP in murine bone remains

376 diverse, with p21+ cells expressing a larger number of SASP factors compared to p16+ cells. (g)

377 In the murine liver (PMID: 34755088, GSE166504), 13 different cell types are identified. (h) The

378 liver has the lowest proportion of p21+ cells from all tissues analyzed, although they still form the

379 majority of senescent cells, with a few dPo cells. (i) The p21-associated SASP is larger compared

380 to the p16-associated SASP, with limited overlapping SASP factors. (j) In a single-cell proteome

381 dataset analyzed by CyTOF in bone (PMID: 37524694), 10 different cell types are distinguished.

382 (k), p21+ cells are present in a higher proportion than p16+ cells, and double-positive cells are

383 rare. (l) The secretome exhibits unique factors for p16+ and p21+ cells, with overlap in *Cxcl12*,

384 *Cxcl1*, and *Tnf*.

385 **Figure 3: Comparative analysis of p16+ and p21+ cells and their SASP in human skin and**

386 **lung during aging** (a) In human skin samples (PMID: 33238152, HRA000395), 16

387 distinguishable cell populations are identified. (b) Among these populations, p21+ cells are

388 notably abundant, while double-positive (dPo) cells are rare. (c) The SASP expressed by p21+

389 cells is significantly larger compared to the SASP associated with p16+ cells. (d) In the human

390 lung (PMID: 37706427, GSE122960, GSE128033, GSE130148, GSE212109), 18 discernible cell

391 types are identified, and (e) within these cell types, p21+ cells constitute the majority of senescent

392 cells. (f) The SASP profile of p21+ cells is extensive compared to that of p16+ cells, with minimal

393 overlap.

394 **Figure 4: Common p16- and p21-associated SASP across murine and human tissues.** (a)

395 The p16-associated SASP is characterized by the predominant presence of *Ccl2* and *Ccl24*, with

396 some markers, such as *Spp1*, expressed in multiple tissues. (b) The p21-associated SASP

397 displays greater diversity, with genes like *lcam1* and *Jun* commonly expressed across tissues.
398 (c) From the SenMayo panel, the p16-core-SASP includes *Spp1*, *Cd9*, *Mif*, *Ctsb*, *Mmp2*, *Igfbp6*,
399 *Hmgb1* and *Igfbp4*. (d) The p21-associated SASP is dominated by *lcam1* and *Jun* that are
400 expressed consistently by p21-positive cells in all six analyzed tissues. (e) A “core”-SASP for
401 senescent cells comprises *Jun*, *Igfbp4*, *Igfbp6* and *Spp1*. (f-h) The secretome associated with
402 both p16 and p21, derived from the SenMayo and whole secretome, exhibits a higher number of
403 shared markers across various tissues. *The depicted genes are those significantly overexpressed*
404 ($p<0.05$, $FC>0$), *with cell type colors corresponding to those in Fig. 1-3. In (a) and (b), the dot size*
405 *reflects the log2FC. For (c), only markers expressed in 2 or more tissues are shown; in (d), those*
406 *expressed in 4 or more tissues; in (f), those expressed in 3 tissues; and in (g), those expressed*
407 *in more than 4 tissues are displayed.*

408

409

410 **Figure 5: Unequal communicational patterns between p21+ and p16+ cells across tissues.**
411 (a) The network centrality scores depict low (blue) and high (red) communication networks for
412 seventeen significant interactions, with p21+ and p16+ cells shown pairwise in each tissue. (b) In
413 the brain, p21+ cells exhibit higher interaction strength in CCL communication, primarily to
414 microglia cells, while p16+ cells demonstrate increased secretory activity via MAG to
415 oligodendrocytes. (c) In bone, p21+ cells exclusively utilize the THBS and FN1 pathways to
416 communicate with hypertrophic chondrocytes, osteoblasts, and lymphocytes. (d) In the skin, p16+
417 cells show higher interaction strength in the CD99 pathway to fibroblasts and melanocytes, while
418 p21+ cells predominantly signal through the DESMOSOME pathway to granular and spinous
419 cells, including sebocytes. (e) In muscle, p21+ cells mainly signal through the COLLAGEN and
420 LAMININ pathways to fibro-adipogenic progenitors (FAPs) and tendon cells, as p16-positive cells
421 are too few for calculating communicational patterns. (f) In the liver, the JAM pathway is
422 predominantly used by p21+ cells to communicate with myofibroblasts and hepatic progenitors,
423 whereas p16+ cells primarily employ the CDH5 pathway to interact with endothelial and Kupffer
424 cells. (g) In the lung, p16+ cells exhibit the highest signaling strength in the CD45 pathway, mainly
425 used to communicate with NK cells and T lymphocytes, while p21+ cells primarily use the MIF
426 pathway for contact with lymphatic endothelial and NK cells.

427 *Displayed are only significant interactions ($padj<0.05$), with cell type colors corresponding to*
428 *those in Figures 1-3. The color scale (blue-white-red) of the interactions in (B-G) corresponds to*
429 *the centrality score in (A).*

430 **Extended data Figure Legends**

431
432

433 **Extended Data Figure 1. Comprehensive examination of the mRNA expression profiles for**
434 **the whole secretome and SenMayo in aging murine hippocampus.** (a) In the murine
435 hippocampus, there is minimal overlap between the mRNA expression of the whole secretome +
436 SenMayo in p21+ and p16+ cells.

437

438 **Extended Data Figure 2. Comprehensive analysis of mRNA expression profiles for the**
439 **whole secretome and SenMayo in aging murine muscle, bone, and liver.** (a) In the muscle,
440 there is some overlap with a noticeably larger p21-associated whole secretome and SenMayo
441 mRNA expression compared to p16. (b) Similar to the muscle, in the bone, this phenomenon is
442 comparable, with some overlap but a more pronounced p21-associated secretome and SenMayo.
443 (c) Within the liver, there is minimal overlap between p21+ cells and p16+ cells, with the p21+
444 cells predominantly expressing the majority of factors.

445

446 **Extended Data Figure 3. Overexpression of p16 and p21 reveals distinct SASP profiles**
447 **(GSE117278).** (a) A PCA plot illustrating control-MEFs on day 4 and 10, as well as p16-
448 overexpressing cells (adeno-Cre-EGFP virus Ai14;L-p16 injection into the tail) on day 4 and 10,
449 compared to p21-overexpressing cells (Ai14;L-p21) on day 4 and 10. (b) A comparable number
450 of SASP factors are expressed in p16 (red)- vs. p21 (blue)-positive cells, with overlap indicated
451 in yellow.

452

453 **Extended Data Figure 4 Analysis of the whole secretome and SenMayo in human skin and**
454 **lung during aging.** (a) In the skin, there is minimal overlap between p16- and p21-positive cells
455 in terms of mRNA expression of the whole secretome and SenMayo. Unlike the majority of
456 examined tissues, the mRNA expression of the entire secretome and SenMayo associated with
457 p16 is as extensive as that associated with p21. (b) In the lung, the p21+ cells express a large
458 number of secreted factors, with a very small overlap with p16+ cells.

459

460 **Extended Data Figure 5. SCENIC analysis of the regulating transcription factors of p16+**
461 **and p21+ cells.** (a) When analyzing five distinct tissues for regulatory factors in p16+ cells, each
462 tissue exhibits a substantial array of transcription factors governing the behavior of p16+ cells.
463 (Since liver has very few p16-positive cells for proper calculation with SCENIC, these were
464 excluded). (b) The x-axis, represents the number of genes, plotted against the y-axis, illustrating
465 the relative activity of the respective transcription factor, highlights the significance of each factor.
466 Interestingly, only four factors (*Sox8*, *Creb3l2*, *Sox10*, and *Relb*) exhibit consistency across
467 multiple tissues in the context of p16-positive cells. (c) In the p21+ cells, the regulating
468 transcription factors show a high heterogeneity across tissues. (d) The transcription factors
469 associated with p21 are predominantly specific to a single organ, but a few transcription factors
470 such as *Erg*, *Sox17*, *Klf4*, *Jun*, *Klf2*, and others, regulate p21+ cells in two tissues.

471

472

473 **References**

474

475 1 Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. *Exp Cell*
476 *Res* **25**, 585-621 (1961).

477 2 Gorgoulis, V. *et al.* Cellular Senescence: Defining a Path Forward. *Cell* **179**, 813-827
478 (2019).

479 3 Coppé, J.-P. *et al.* Senescence-Associated Secretory Phenotypes Reveal Cell-
480 Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor. *PLOS*
481 **Biology** **6**, e301, doi:10.1371/journal.pbio.0060301 (2008).

482 4 Muñoz-Espín, D. *et al.* Programmed Cell Senescence during Mammalian Embryonic
483 Development. *Cell* **155**, 1104-1118, doi:<http://dx.doi.org/10.1016/j.cell.2013.10.019>
484 (2013).

485 5 Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras
486 Provokes Premature Cell Senescence Associated with Accumulation of p53 and
487 p16INK4a. *Cell* **88**, 593-602 (1997).

488 6 Demaria, M. *et al.* An essential role for senescent cells in optimal wound healing through
489 secretion of PDGF-AA. *Dev Cell* **31**, 722-733, doi:10.1016/j.devcel.2014.11.012 (2014).

490 7 Robbins, P. D. *et al.* Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health
491 Span. *Annu Rev Pharmacol Toxicol* **61**, 779-803, doi:10.1146/annurev-pharmtox-050120-
492 105018 (2021).

493 8 Hernandez-Segura, A. *et al.* Unmasking Transcriptional Heterogeneity in Senescent Cells.
494 *Curr Biol* **27**, 2652-2660.e2654, doi:10.1016/j.cub.2017.07.033 (2017).

495 9 Gurkar, A. U. *et al.* Spatial mapping of cellular senescence: emerging challenges and
496 opportunities. *Nat Aging* **3**, 776-790, doi:10.1038/s43587-023-00446-6 (2023).

497 10 Ogrodnik, M. *et al.* Whole-body senescent cell clearance alleviates age-related brain
498 inflammation and cognitive impairment in mice. *Aging Cell* **20**, e13296,
499 doi:10.1111/ace.13296 (2021).

500 11 Martin, E., El-Behi, M., Fontaine, B. & Delarasse, C. Analysis of Microglia and Monocyte-
501 derived Macrophages from the Central Nervous System by Flow Cytometry. *J Vis Exp*,
502 doi:10.3791/55781 (2017).

503 12 Gire, V. & Dulic, V. Senescence from G2 arrest, revisited. *Cell Cycle* **14**, 297-304,
504 doi:10.1080/15384101.2014.1000134 (2015).

505 13 Saul, D. *et al.* A new gene set identifies senescent cells and predicts senescence-
506 associated pathways across tissues. *Nat Commun* **13**, 4827, doi:10.1038/s41467-022-
507 32552-1 (2022).

508 14 Uhlén, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science* **347**,
509 1260419, doi:10.1126/science.1260419 (2015).

510 15 Zhang, X. *et al.* Characterization of cellular senescence in aging skeletal muscle. *Nat*
511 *Aging* **2**, 601-615, doi:10.1038/s43587-022-00250-8 (2022).

512 16 Farr, J. N. *et al.* Targeting cellular senescence prevents age-related bone loss in mice.
513 *Nature medicine* **23**, 1072-1079, doi:10.1038/nm.4385 (2017).

514 17 Ogrodnik, M. *et al.* Cellular senescence drives age-dependent hepatic steatosis. *Nat*
515 *Commun* **8**, 15691, doi:10.1038/ncomms15691 (2017).

516 18 Sturmlechner, I. *et al.* p21 produces a bioactive secretome that places stressed cells under
517 immunosurveillance. *Science* **374**, eabb3420, doi:10.1126/science.abb3420 (2021).

518 19 Doolittle, M. L. *et al.* Multiparametric senescent cell phenotyping reveals targets of
519 senolytic therapy in the aged murine skeleton. *Nat Commun* **14**, 4587,
520 doi:10.1038/s41467-023-40393-9 (2023).

521 20 Zou, Z. *et al.* A Single-Cell Transcriptomic Atlas of Human Skin Aging. *Dev Cell* **56**, 383-
522 397.e388, doi:10.1016/j.devcel.2020.11.002 (2021).

523 21 Jia, M. *et al.* Transcriptional changes of the aging lung. *Aging Cell* **22**, e13969,
524 doi:10.1111/ace.13969 (2023).

525 22 Uhlén, M. *et al.* The human secretome. *Sci Signal* **12**, doi:10.1126/scisignal.aaz0274
526 (2019).

527 23 Acosta, J. C. *et al.* A complex secretory program orchestrated by the inflammasome
528 controls paracrine senescence. *Nat Cell Biol* **15**, 978-990 (2013).

529 24 Saul, D. *et al.* Modulation of fracture healing by the transient accumulation of senescent
530 cells. *Elife* **10**, doi:10.7554/elife.69958 (2021).

531 25 Moiseeva, V. *et al.* Senescence atlas reveals an aged-like inflamed niche that blunts
532 muscle regeneration. *Nature* **613**, 169-178, doi:10.1038/s41586-022-05535-x (2023).

533 26 Lagnado, A. *et al.* Neutrophils induce paracrine telomere dysfunction and senescence in
534 ROS-dependent manner. *Embo j* **40**, e106048, doi:10.15252/embj.2020106048 (2021).

535 27 Jin, S. *et al.* Inference and analysis of cell-cell communication using CellChat. *Nat
536 Commun* **12**, 1088, doi:10.1038/s41467-021-21246-9 (2021).

537 28 Aibar, S. *et al.* SCENIC: single-cell regulatory network inference and clustering. *Nature
538 Methods* **14**, 1083-1086, doi:10.1038/nmeth.4463 (2017).

539 29 Maciel-Barón, L. A. *et al.* Senescence associated secretory phenotype profile from primary
540 lung mice fibroblasts depends on the senescence induction stimuli. *Age (Dordr)* **38**, 26,
541 doi:10.1007/s11357-016-9886-1 (2016).

542 30 Serrano, M., Hannon, G. J. & Beach, D. A new regulatory motif in cell-cycle control causing
543 specific inhibition of cyclin D/CDK4. *Nature* **366**, 704-707, doi:10.1038/366704a0 (1993).

544 31 Rayess, H., Wang, M. B. & Srivatsan, E. S. Cellular senescence and tumor suppressor
545 gene p16. *Int J Cancer* **130**, 1715-1725, doi:10.1002/ijc.27316 (2012).

546 32 Cohn, R. L., Gasek, N. S., Kuchel, G. A. & Xu, M. The heterogeneity of cellular
547 senescence: insights at the single-cell level. *Trends in Cell Biology* **33**, 9-17,
548 doi:<https://doi.org/10.1016/j.tcb.2022.04.011> (2023).

549 33 Stein, G. H., Drullinger, L. F., Soulard, A. & Dulic, V. Differential roles for cyclin-dependent
550 kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in
551 human fibroblasts. *Mol Cell Biol* **19**, 2109-2117, doi:10.1128/mcb.19.3.2109 (1999).

552 34 Yosef, R. *et al.* p21 maintains senescent cell viability under persistent DNA damage
553 response by restraining JNK and caspase signaling. *The EMBO Journal* **36**, 2280-2295,
554 doi:<https://doi.org/10.15252/embj.201695553> (2017).

555 35 Chandra, A. *et al.* Targeted clearance of p21- but not p16-positive senescent cells
556 prevents radiation-induced osteoporosis and increased marrow adiposity. *Aging Cell* **21**,
557 e13602, doi:10.1111/acel.13602 (2022).

558




Figure 1: Distinct p16+ and p21+ cell populations with differential SASPs in the murine hippocampus **(a)** A tSNE plot depicting the five main populations of young and old murine hippocampus (PMID: 33470505, GSE161340). **(b)** From the original population, CD45- cells are selected, followed by Ki67-negativity and cells not in the S phase. From these cells, just p16(*Cdkn2a*)+ cells and p21(*Cdkn1a*)+ cells are selected. From the p16+ cells, microglia and oligodendrocytes depict the main populations, while in the p21+ population, microglia is predominant. **(c)** tSNE visualization of p16 (red) and p21 (blue) cells, along with few double-positive cells (green), shown in the Cd45-Ki67-S- population. **(d)** The dPo (double positive) cells are high in both *Cdkn2a* and *Cdkn1a* while p16+ cells just express *Cdkn2a*, but no *Cdkn1a* and vice versa. **(e)** Utilizing the SenMayo gene set, SASP factors exclusively expressed by p16+ cells are fewer than those expressed in p21+ cells, with some (*Cxcl16*, *Plaur*) being expressed by both. Very few SASP genes are expressed by p16-negative and p21-negative cells. The size of the dots represents the fold change compared to all other populations shown in (c).




Figure 2: Comparative analysis of p16+ and p21+ cells and their SASP in different murine tissues during aging. (a) In murine skeletal muscle (PMID: 36147777, GSE172410), nine different cell types can be distinguished. (b) p21+ cells constitute the majority, while double positive (dPo) cells are infrequent. (c) The SASP is heterogeneous, with p21+ cells expressing a vast array of SASP factors, exhibiting minimal overlap with p16-associated SASP factors. (d) In murine bone (PMID: 31130381, GSE128423), 17 cell types can be distinguished. (e) p21+ cells once again dominate the senescent cell population, and the (f) SASP in murine bone remains diverse, with p21+ cells expressing a larger number of SASP factors compared to p16+ cells. (g) In the murine liver (PMID: 34755088, GSE166504), 13 different cell types are identified. (h) The liver has the lowest proportion of p21+ cells from all tissues analyzed, although they still form the majority of senescent cells, with a few dPo cells. (i) The p21-associated SASP is larger compared to the p16-associated SASP, with limited overlapping SASP factors. (j) In a single-cell proteome dataset analyzed by CyTOF in bone (PMID: 37524694), 10 different cell types are distinguished. (k) p21+ cells are present in a higher proportion than p16+ cells, and double-positive cells are rare. (l) The secretome exhibits unique factors for p16+ and p21+ cells, with overlap in Cxcl12, Cxcl1, and Tnf.




Figure 3: Comparative analysis of p16+ and p21+ cells and their SASP in human skin and lung during aging **(a)** In human skin samples (PMID: 33238152, HRA000395), 16 distinguishable cell populations are identified. **(b)** Among these populations, p21+ cells are notably abundant, while double-positive (dPo) cells are rare. **(c)** The SASP expressed by p21+ cells is significantly larger compared to the SASP associated with p16+ cells. **(d)** In the human lung (PMID: 37706427, GSE122960, GSE128033, GSE130148, GSE212109), 18 discernible cell types are identified, and **(e)** within these cell types, p21+ cells constitute the majority of senescent cells. **(f)** The SASP profile of p21+ cells is extensive compared to that of p16+ cells, with minimal overlap.




Figure 4: Common p16- and p21-associated SASP across murine and human tissues. (a) The p16-associated SASP is characterized by the predominant presence of *Ccl2* and *Ccl24*, with some markers, such as *Spp1*, expressed in multiple tissues. (b) The p21-associated SASP displays greater diversity, with genes like *Icam1* and *Jun* commonly expressed across tissues. (c) From the SenMayo panel, the p16-core-SASP includes *Spp1*, *Cd9*, *Mif*, *Ctsb*, *Mmp2*, *Igfbp6*, *Hmgb1* and *Igfbp4*. (d) The p21-associated SASP is dominated by *Icam1* and *Jun* that are expressed consistently by p21-positive cells in all six analyzed tissues. (e) A “core”-SASP for senescent cells comprises *Jun*, *Igfbp4*, *Igfbp6* and *Spp1*. (f-h) The secretome associated with both p16 and p21, derived from the SenMayo and whole secretome, exhibits a higher number of shared markers across various tissues. *The depicted genes are those significantly overexpressed (p<0.05, FC>0), with cell type colors corresponding to those in Fig. 1-3. In (a) and (b), the dot size reflects the log2FC. For (c), only markers expressed in 2 or more tissues are shown; in (d), those expressed in 4 or more tissues; in (f), those expressed in 3 tissues; and in (g), those expressed in more than 4 tissues are displayed.*






Figure 5: Unequal communicational patterns between p21+ and p16+ cells across tissues.

(a) The network centrality scores depict low (blue) and high (red) communication networks for seventeen significant interactions, with p21+ and p16+ cells shown pairwise in each tissue. **(b)** In the brain, p21+ cells exhibit higher interaction strength in CCL communication, primarily to microglia cells, while p16+ cells demonstrate increased secretory activity via MAG to oligodendrocytes. **(c)** In bone, p21+ cells exclusively utilize the THBS and FN1 pathways to communicate with hypertrophic chondrocytes, osteoblasts, and lymphocytes. **(d)** In the skin, p16+ cells show higher interaction strength in the CD99 pathway to fibroblasts and melanocytes, while p21+ cells predominantly signal through the DESMOSOME pathway to granular and spinous cells, including sebocytes. **(e)** In muscle, p21+ cells mainly signal through the COLLAGEN and LAMININ pathways to fibro-adipogenic progenitors (FAPs) and tendon cells, as p16-positive cells are too few for calculating communicational patterns. **(f)** In the liver, the JAM pathway is predominantly used by p21+ cells to communicate with myofibroblasts and hepatic progenitors, whereas p16+ cells primarily employ the CDH5 pathway to interact with endothelial and Kupffer cells. **(g)** In the lung, p16+ cells exhibit the highest signaling strength in the CD45 pathway, mainly used to communicate with NK cells and T lymphocytes, while p21+ cells primarily use the MIF pathway for contact with lymphatic endothelial and NK cells.


Displayed are only significant interactions (padj<0.05), with cell type colors corresponding to those in Figures 1-3. The color scale (blue-white-red) of the interactions in (B-G) corresponds to the centrality score in (A).




Extended Data Figure 1. Comprehensive examination of the mRNA expression profiles for the whole secretome and SenMayo in aging murine hippocampus. (a) In the murine hippocampus, there is minimal overlap between the mRNA expression of the whole secretome + SenMayo in p21+ and p16+ cells.



b




C




Extended Data Figure 2. Comprehensive analysis of mRNA expression profiles for the whole secretome and SenMayo in aging murine muscle, bone, and liver. (a) In the muscle, there is some overlap with a noticeably larger p21-associated whole secretome and SenMayo mRNA expression compared to p16. (b) Similar to the muscle, in the bone, this phenomenon is comparable, with some overlap but a more pronounced p21-associated secretome and SenMayo. (c) Within the liver, there is minimal overlap between p21+ cells and p16+ cells, with the p21+ cells predominantly expressing the majority of factors.

a




b




Extended Data Figure 3. Overexpression of p16 and p21 reveals distinct SASP profiles (GSE117278). (a) A PCA plot illustrating control-MEFs on day 4 and 10, as well as p16-overexpressing cells (adeno-Cre-EGFP virus Ai14;L-p16 injection into the tail) on day 4 and 10, compared to p21-overexpressing cells (Ai14;L-p21) on day 4 and 10. (b) A comparable number of SASP factors are expressed in p16 (red)- vs. p21 (blue)-positive cells, with overlap indicated in yellow.


a



b



Extended Data Figure 4 Analysis of the whole secretome and SenMayo in human skin and lung during aging. (a) In the skin, there is minimal overlap between p16- and p21-positive cells in terms of mRNA expression of the whole secretome and SenMayo. Unlike the majority of examined tissues, the mRNA expression of the entire secretome and SenMayo associated with p16 is as extensive as that associated with p21. (b) In the lung, the p21+ cells express a large number of secreted factors, with a very small overlap with p16+ cells.



Extended Data Figure 5. SCENIC analysis of the regulating transcription factors of p16+ and p21+ cells. (a) When analyzing five distinct tissues for regulatory factors in p16+ cells, each tissue exhibits a substantial array of transcription factors governing the behavior of p16+ cells. (Since liver has very few p16-positive cells for proper calculation with SCENIC, these were excluded). (b) The x-axis, represents the number of genes, plotted against the y-axis, illustrating the relative activity of the respective transcription factor, highlights the significance of each factor. Interestingly, only four factors (*Sox8*, *Creb3l2*, *Sox10*, and *Relb*) exhibit consistency across multiple tissues in the context of p16-positive cells. (c) In the p21+ cells, the regulating transcription factors show a high heterogeneity across tissues. (d) The transcription factors associated with p21 are predominantly specific to a single organ, but a few transcription factors such as *Erg*, *Sox17*, *Klf4*, *Jun*, *Klf2*, and others, regulate p21+ cells in two tissues.